Telman

Telmisartan

Alone or in combination w/ other antihypertensives for HTN.

Initially 40 mg once daily, may be increased to max of 80 mg once daily.

May be taken with or without food.

Hypersensitivity. Biliary obstructive disorders. Concomitant use w/ aliskiren-containing products in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m²). Severe hepatic impairment. Pregnancy (2nd & 3rd trimester).

Dual blockade of renin-angiotensin-aldosterone system (RAAS) through combination w/ ACE inhibitors or aliskiren is not recommended. Not recommended in patients w/ primary aldosteronism. Increased risk of severe hypotension & renal insufficiency in patients w/ bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney. MI or stroke in excessive reduction of BP in patients w/ ischaemic cardiopathy or ischaemic CV disease. Patients w/ severe CHF or underlying renal disease including renal artery stenosis; aortic or mitral stenosis or obstructive hypertrophic cardiomyopathy; risk factors for hyperkalemia eg, DM, concomitant use w/ ≥1 other medicinal products that affect the RAAS &/or K supplements, medicinal products that may provoke hyperkalemia; intercurrent events particularly dehydration, acute cardiac decompensation, metabolic acidosis, sudden worsening of renal condition (eg, infectious diseases), cellular lysis (eg, acute limb ischaemia, rhabdomyolysis, extend trauma). Black people. Correct vol &/or Na depletion prior to administration. Monitor blood glucose in diabetic patients treated w/ insulin or antidiabetics. Not to be concomitantly used w/ ACE inhibitors in patients w/ diabetic nephropathy. Not to be taken by patients w/ galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Not to be given to patients w/ cholestasis, biliary obstructive disorders or severe hepatic impairment. Mild-moderate hepatic impairment. Periodically monitor K & creatinine serum levels in patients w/ renal impairment. Recent kidney transplantation. Not to be initiated during pregnancy. Not recommended during lactation. Elderly >70 yr.

Increased peak & trough plasma conc of digoxin. May increase risk of hyperkalemia w/ other medicinal products that may provoke hyperkalemia eg, salt substitutes containing K, K-sparing diuretics, ACE inhibitors, AIIA, NSAIDs (including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus) & trimethoprim. Attenuated diuretic-induced K loss w/ K-sparing diuretics (eg, spirinolactone, eplerenone, triamterene or amiloride), K supplements or K-containing salt substitutes. Increased serum conc & toxicity of lithium. Antihypertensive effect may be reduced w/ NSAIDs (ie, ASA at anti-inflammatory dose, COX-2 inhibitors & non-selective NSAIDs). May result in vol depletion w/ furosemide & hydrochlorothiazide. Increased BP-lowering effect w/ other antihypertensives. Higher frequency of adverse events in dual blockade of the RAAS through combination w/ ACE inhibitors or aliskiren. Hypotensive effects may be potentiated w/ baclofen, amifostine. May aggravate orthostatic hypotension w/ alcohol, barbiturates, narcotics or antidepressants. Reduced antihypertensive effects w/ systemic corticosteroids.

Angiotensin II Antagonists

C09CA07 - telmisartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Rx